Skip to main content

Table 3 Association of TyG, sICAS, and ICASB with ischemic stroke recurrence

From: Triglyceride-glucose index, symptomatic intracranial artery stenosis and recurrence risk in minor stroke patients with hypertension

Variable

No. total

No. event (%)

Unadjusted HR (95% CI)

P value

Model I HR (95% CI)

P value

Model II HR (95% CI)

P value

Model III HR (95% CI)

P value

TyG (continuous)

1281

117 (9.1)

1.15 (0.9–1.47)

0.254

1.12 (0.86–1.46)

0.388

1.04 (0.78–1.38)

0.812

1.13 (0.85–1.49)

0.403

TyG (categories)

          

 TyG quartile 1

320

19 (5.9)

1 (Ref.)

 

1 (Ref.)

 

1 (Ref.)

 

1 (Ref.)

 

 TyG quartile 2

320

32 (10)

1.73 (0.98–3.05)

0.059

1.85 (1.02–3.36)

0.043

1.82 (0.97–3.41)

0.061

1.72 (0.91–3.26)

0.065

 TyG quartile 3

320

32 (10)

1.72 (0.98–3.04)

0.061

1.85 (1.01–3.38)

0.046

1.88 (1.01–3.53)

0.048

1.96 (1.05–3.66)

0.043

0.010

 TyG quartile 4

321

34 (10.6)

1.84 (1.05–3.23)

0.033

1.9 (1.04–3.48)

0.038

1.91 (1.12–3.15)

0.027

2.02 (1.07–3.84)

0.025

ICASB (continuous)

1281

117 (9.1)

1.07 (1.03–1.12)

0.001

1.08 (1.04–1.13)

 < 0.001

1.08 (1.03–1.13)

0.003

1.08 (1.03–1.13)

0.002

ICASB (categories)

          

 ICASB < 4

922

70 (7.6)

1 (Ref.)

 

1 (Ref)

 

1 (Ref.)

 

1 (Ref.)

 

 ICASB 4–5

137

17 (12.4)

1.67 (0.98–2.84)

0.058

1.84 (1.07–3.14)

0.026

1.57 (0.88–2.79)

0.125

1.73 (1–2.99)

0.05

 ICASB > 5

222

30 (13.5)

1.8 (1.18–2.76)

0.007

1.86 (1.18–2.92)

0.007

1.82 (1.14–2.92)

0.012

1.76 (1.1–2.81)

0.018

sICAS

          

 Without sICAS

943

70 (7.4)

1 (Ref.)

 

1 (Ref.)

 

1 (Ref.)

 

1 (Ref.)

 

 With sICAS

338

47 (13.9)

1.89 (1.31–2.74)

0.001

1.94 (1.32–2.84)

0.001

1.73 (1.16–2.59)

0.007

1.65 (1.1–2.46)

0.014

  1. The effects of TyG, sICAS, and ICASB on ischemic stroke recurrence were analyzed using univariate and multifactorial Cox regression models. Model I was adjusted for age and sex, and model II was further adjusted for BMI, SBP, smoking status, time at onset, NIHSS score at arrival, WBC count, previous stroke, and previous diabetes mellitus. Model III was further adjusted for treatment during admission (antiplatelet and intensive statin therapy) and antihypertensive and hypoglycemic treatment on the basis of model II